Laura Langevin
Psychiatric/Mental Health · Cumberland, RINPI 1023765930
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,393 and has fallen 78.0% since, to $307 in 2025.
Across 161 payments — averaging $21.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$526
- Teva Pharmaceuticals USA, Inc.$446
- Lundbeck LLC$429
- Neurocrine Biosciences, Inc.$350
- Alkermes, Inc.$348
- AbbVie$313
- plus $988 from 10 others
What the payments were for
- Food & beverage$3,389100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 26 | $526 |
| Teva Pharmaceuticals USA, Inc. | 17 | $446 |
| Lundbeck LLC | 21 | $429 |
| Neurocrine Biosciences, Inc. | 16 | $350 |
| Alkermes, Inc. | 18 | $348 |
| AbbVie | 22 | $313 |
| Axsome Therapeutics, Inc. | 7 | $199 |
| Corium, LLC | 8 | $146 |
| Johnson & Johnson | 5 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $126 |
| Vanda Pharmaceuticals Inc. | 4 | $105 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $91 |
| E.r. Squibb & Sons, L.L.C. | 3 | $81 |
| Tempus AI, Inc | 2 | $59 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
How this compares
$3,399 in reported general payments places this provider in the 85th percentile of 196 psychiatric/mental health providers in Rhode Island.
See all psychiatric/mental health providers in Rhode Island →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 17 | $25,038 |
| SpravatoEsketamine Hcl | 11 | $13,686 |
| Bupropion XlBupropion Hcl | 31 | $1,163 |
| Quetiapine Fumarate | 40 | $898 |
| Carbamazepine ErCarbamazepine | 12 | $562 |
| Duloxetine Hcl | 29 | $516 |
| Haloperidol | 15 | $505 |
| Buspirone Hcl | 20 | $403 |
| Prazosin Hcl | 12 | $351 |
| Olanzapine | 16 | $288 |
| Benztropine Mesylate | 23 | $278 |
| Sertraline Hcl | 36 | $257 |
| Escitalopram Oxalate | 20 | $250 |
| Fluoxetine Hcl | 23 | $221 |
| Donepezil Hcl | 14 | $196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $526 | $25,03817 claims |
| Johnson & JohnsonSpravato | $132 | $13,68611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 196 psychiatric/mental health providers in Rhode Island.
Other psychiatric/mental health in Cumberland
- Samantha Shawn MarshBradford$639K
- Samuel KaufmanRiverside$19K
- Katie ThayerWarwick$16K
- Arielle RoundsWarwick$15K
- Eniayo EgberongbeCranston$12K
- Deborah HorvitzWarwick$10K
- Donna McDonaldProvidence$9K
- Timothy PepinNorth Smithfield$9K
- Anita ObengCranston$8K
- Alyssa KortschinskyWarwick$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.